Who Paid My Doc
Scott Long
Anatomic Pathology & Clinical Pathology Houston, TX Medical Doctor
NPI 1760637284 CMS profile 1378986
6565 Fannin, M227, Houston, TX 77030
General payments
$3,796
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$125,040
Through program year 2025, Scott Long of Houston, TX is reported in the CMS Open Payments database as having received $3,796 across 40 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $125,040 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 92nd percentile of Anatomic Pathology & Clinical Pathology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $691 | 3 | |
| 2024 | General | $54 | 3 | |
| 2023 | General | $29 | 1 | |
| 2022 | General | $146 | 6 | |
| 2021 | General | $16 | 1 | |
| 2020 | General | $523 | 3 | |
| 2019 | General | $2,338 | 23 |
Beside peers
- Scott Long
- Anatomic Pathology & Clinical Pathology median
- Middle half of Anatomic Pathology & Clinical Pathology
- National median
In program year 2025, general payments to Scott Long were reported at $691. Among 2,804 Anatomic Pathology & Clinical Pathology profiles paid that year, the median was $51 and the middle half received between $24 and $149.
Show as a table
| Year | Scott Long | Anatomic Pathology & Clinical Pathology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $2,338 | $65 | $22–$150 | $163 |
| 2020 | $523 | $44 | $19–$144 | $114 |
| 2021 | $16 | $42 | $19–$142 | $132 |
| 2022 | $146 | $54 | $20–$140 | $149 |
| 2023 | $29 | $60 | $23–$157 | $160 |
| 2024 | $54 | $51 | $23–$145 | $164 |
| 2025 | $691 | $51 | $24–$149 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Records
40 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Anatomic Pathology & Clinical Pathology in Texas
Christopher Bibb
Anatomic Pathology & Clinical Pathology · Bryan, TX
Rabia Shafi
Anatomic Pathology & Clinical Pathology · Houston, TX
Robert Brady
Anatomic Pathology & Clinical Pathology · Fort Sam Houston, TX
Scott Lloyd
Anatomic Pathology & Clinical Pathology · Tyler, TX
Jason Gregorio
Anatomic Pathology & Clinical Pathology · Houston, TX
Elizabeth Schanzmeyer
Anatomic Pathology & Clinical Pathology · Fort Cavazos, TX
Related records
Anatomic Pathology & Clinical Pathology in Texas
Practitioners in the same specialty and state, ranked by reported value.
All Anatomic Pathology & Clinical Pathology
Everyone recorded under this specialty, nationwide.
Doctors in Texas
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.